Last edition
News about "ONO Pharmaceutical "
Ono Pharma Enters into Drug Discovery Partnership with Aitia in Neurological Diseases
Ono Pharma partners with Aitia to use causal Artificial Intelligence (AI) and Gemini Digital Twins for novel drug target discovery in neurological diseases.
Ono Pharmaceutical | 03/09/2026 | By News Bureau
Mediar Therapeutics, Ono Pharma Enter Collaboration to Develop Novel Fibrosis Therapies
Mediar Therapeutics and Ono Pharmaceutical have entered a collaboration and option agreement to discover novel therapies targeting fibro-inflammatory diseases, while Mediar advances its pipeline of fibrosis-focused antibody programmes.
Ono Pharmaceutical | 10/08/2026 | By News Bureau | 117
Ono Pharma Seeks Expanded OPDIVO Use for Anaplastic Thyroid Cancer in Japan
Ono Pharma seeks expanded approval for OPDIVO in Japan for unresectable anaplastic thyroid cancer after a trial with Lenvima met its primary endpoint.
Ono Pharmaceutical | 12/06/2026 | By News Bureau | 166
Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery
Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics, leveraging the Revenir platform to discover small molecule modulators in neurology and immunology. Ono will hold exclusive worldwide option rights for development and commercialisation of resulting candidates.
Ono Pharmaceutical | 03/03/2026 | By Akanki | 209
Ono Pharmaceutical has signed a definitive agreement with Seikagaku Corporation for the co-development and exclusive marketing of Gel-One for osteoarthritis treatment in Japan.
Ono Pharmaceutical | 11/08/2025 | By Mrinmoy Dey | 412
Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area
Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™.
Ono Pharmaceutical | 07/12/2024 | By Aishwarya | 531
Ono Announces Acquisition of Deciphera Pharmaceuticals
Ono Pharmaceutical, Co., Ltd. has completed the tender offer to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. for USD 25.60 per share (total amount of approximately USD 2.4 billion) net to the seller in cash.
Ono Pharmaceutical | 14/06/2024 | By Aishwarya | 902
ONO to Acquire Deciphera Pharma for USD 2.4 Billion
Deciphera Pharmaceuticals, Inc. has signed a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO).
ONO Pharmaceutical | 30/04/2024 | By Aishwarya | 1709
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy